A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02431468 |
|
Recruitment Status :
Completed
First Posted : May 1, 2015
Results First Posted : July 6, 2018
Last Update Posted : July 6, 2018
|
Sponsor:
Neurotrope Bioscience, Inc.
Information provided by (Responsible Party):
Neurotrope Bioscience, Inc.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease. The study is 15 weeks in duration, including a safety and efficacy evaluation 30 days after the last dose of study drug.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Alzheimer's Disease | Drug: Bryostatin 1 Other: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 147 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease |
| Study Start Date : | November 2015 |
| Actual Primary Completion Date : | February 2017 |
| Actual Study Completion Date : | February 2017 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Alzheimer disease
MedlinePlus related topics:
Alzheimer's Disease
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Bryostatin 1 20ug
Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
|
Drug: Bryostatin 1
The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
Other Name: bryostatin |
|
Experimental: Bryostatin 1 40ug
Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
|
Drug: Bryostatin 1
The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
Other Name: bryostatin |
|
Placebo Comparator: Placebo
Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.
|
Other: Placebo
The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution. |
Primary Outcome Measures :
- Safety: Number of Subjects With Treatment-emergent Adverse Events and Serious Adverse Events [ Time Frame: Baseline through 30 days post end of treatment (up to Day 107) ]Evaluations of adverse events (AEs), serious adverse events (SAEs), Adverse event of special interest - myalgia
- Efficacy: Change From Baseline in Severe Impairment Battery (SIB) in the Full Analysis Set (FAS) [ Time Frame: Primary analysis at Week 13 (day 91) after 12 weeks of treatment (up to day 107) ]The primary statistical objective for efficacy was to estimate the effect of bryostatin on the mean change in the total SIB score after 12 weeks of treatment, assessed at Week 13 (day 91). Efficacy analyses were conducted according to randomized groups. The SIB is used to assess cognition in subjects with moderate and severe AD. It is divided into nine subscales that include attention, language, orientation, memory, praxis, visuospatial ability, construction, social skills, orienting head to name. Non-verbal responses are allowed, thus decreasing the need for language output. Forty questions are included with a point score range of 0-100. Lower scores indicate greater cognitive impairment.
Secondary Outcome Measures :
- Secondary Efficacy Endpoints [ Time Frame: Week 5, Week 9, Week 13 ]
- Change from baseline in the Severe Impairment Battery (SIB) at Weeks 5 and 9. Assesses cognition. Score range 0-100. Lower scores indicate greater cognitive impairment.
- Change from baseline in Alzheimer Disease Cooperative Study Activities of Daily Living Inventory-Severe Impairment Version (ADCS-ADL-SEV) at Weeks 5, 9,13. A 19-item test of the performance of activities of daily living. Total score range 0-54; lower scores indicate greater functional impairment.
- Change from baseline in MMSE-2 at Weeks 5, 9 and 13. Tests selected aspects of cognition on a scale of 0-30. Lower scores indicate greater cognitive impairment.
- Change from baseline in Neuropsychiatric Inventory (NPI) at Weeks 5, 9,13. Caregiver interview assesses 12 behavioral disturbances. Scores range from 0-144; higher scores indicate greater behavioral disturbances.
- Clinical Global Impression of Improvement (CGI-I) at Weeks 5, 9, 13. A 7-point scale range from (1) very much improved to (7) very much worse.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 55 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Written informed consent from caregiver and subject (if possible) or legally acceptable representative if different from caregiver
- Male and female subjects 55-85 years of age inclusive
- Cognitive deficit present for at least 2 years that meet the diagnostic criteria for probable Alzheimer's
- Mini Mental State Exam (MMSE-2) score of 4-15
- Patients must be able to perform at least one item on the Severe Impairment Battery Scale
- Neuroimaging (computerized tomography (CT) or Magnetic Resonance Imaging (MRI)) within the last 24 months consistent with a diagnosis of probable Alzheimer's disease (AD)
- Reliable caregiver(s) or informant(s) who attends the subject at least an average of 3 hours or more per day for 3 or more days per week
- Adequate vision and motor function to comply with testing
- If taking drugs approved for treatment of Alzheimer's disease (e.g. cholinesterase inhibitors, memantine), must be on a stable dose for at least 3 months prior to entry into study and the dose must not change during the study unless a change is required due to an adverse event or a clinically significant change in the patient's status.
Exclusion Criteria:
- Dementia due to any condition other than AD, including vascular dementia (Rosen-modified Hachinski lschemic score ≥ 5)
- Evidence of significant central nervous system (CNS) vascular disease on previous neuroimaging including but not limited to: cortical stroke, multiple infarcts, localized single infarcts in the thalamus, angular gyrus, multiple lacunar infarcts or extensive white matter injury
- Clinically significant neurologic disease or condition other than AD, such as cerebral tumor, chronic subdural fluid collections, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, or any other diagnosis that could interfere with assessment of safety and efficacy
- Evidence of clinically significant unstable cardiovascular, pulmonary, renal, hepatic, gastrointestinal, neurologic, or metabolic disease within the 6 months prior to enrollment
- Poorly controlled diabetes, at the discretion of the Principal Investigator
- Creatinine clearance (CL) of <45ml/min
- Use of an active Alzheimer's vaccine within 2 years prior to screening
- Use of a monoclonal antibody for treatment of AD within 1 year prior to screening
- Any medical or psychiatric condition that is likely to require initiation of additional medication or surgical intervention during the course of the study
- Use of an investigational drug within 30 days prior to screening
- Prior exposure to bryostatin, or known sensitivity to bryostatin or any ingredient in the study drug
- Any other concurrent medical condition, which in the opinion of the PI makes the subject unsuitable for the clinical study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02431468
Locations
Show 29 study locations
Sponsors and Collaborators
Neurotrope Bioscience, Inc.
Study Documents (Full-Text)
Documents provided by Neurotrope Bioscience, Inc.:
Documents provided by Neurotrope Bioscience, Inc.:
Study Protocol [PDF] March 3, 2017
Statistical Analysis Plan [PDF] March 17, 2017
| Responsible Party: | Neurotrope Bioscience, Inc. |
| ClinicalTrials.gov Identifier: | NCT02431468 |
| Other Study ID Numbers: |
NTRP-101-202 |
| First Posted: | May 1, 2015 Key Record Dates |
| Results First Posted: | July 6, 2018 |
| Last Update Posted: | July 6, 2018 |
| Last Verified: | June 2018 |
Additional relevant MeSH terms:
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases |
Neurocognitive Disorders Mental Disorders Bryostatin 1 Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents |